Preliminary Approval of Settlement with Direct Purchaser Class: In Re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (E.D. Pa.)

10/30/23 | Court Grants Preliminary Approval to $385M Settlement between Indivior, Inc. and Direct Purchaser Class

On Oct. 30, 2023, Judge Mitchell S. Goldberg of the Eastern District of Pennsylvania granted preliminary approval to a settlement between the direct purchaser class and the defendant, Indivior, Inc., in the In Re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation. The $385 million settlement is on behalf of an already certified class consisting of all persons or entities in the United States and its territories who purchased branded Suboxone tablets directly from Reckitt Benckiser Pharmaceuticals Inc. (now known as Indivior, Inc.) from Jan. 1, 2012 through March 14, 2013.

The deadline to object to the settlement has been set for Jan. 12, 2024, and a fairness hearing on final approval will be held on Feb. 27, 2024 in the Eastern District of Pennsylvania before Judge Goldberg.  Click this link for the Order Granting Direct Purchaser Class Plaintiffs’ Motion for Preliminary Approval of Proposed Settlement, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for a Fairness Hearing.

Information concerning the settlement agreement, the address of claims administrator (RG/2), and the Plan of Allocation are available in this link to the Direct Purchaser Class Plaintiffs’ Motion for Preliminary Approval of Proposed Settlement, Approval of the Form and Manner of Notice to the Class and Proposed Schedule for a Fairness Hearing.

11/21/23 | Notice and Claim Form for Settlement with Direct Purchaser Class: In Re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (E.D. Pa.)

Please find below the Notice of Setttlement and Claim Form for the Setttlement with the Direct Purchaser Class  in In Re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (E.D. Pa.), which was preliminarily approved by the Court on Oct. 30, 2023.

Posted below is Class Counsel’s Motion for Attorney’s Fees in In Re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (E.D. Pa.), which was filed on Dec. 29, 2023.

Posted below is the Class Counsel’s Supplemental Submission re Motion for Award of Attorneys’ Fees, Reimbursement of Expenses & Service Awards for Class Representatives.

Posted below is the Notice Of Joinder By Class Representative Rochester Drug Co-Operative, Inc. and Absent Class Member Miami-Luken, Inc.

Posted below is the Opinion and Order of Final Approval of Settlement, Attorney Fees and Incentive Awards.